EHA 2011 - European Hematology Association - June 2011
Chronic Myeloid Leukemia - CML
Some interesting abstracts for CML
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response
ARTICLES
Webcasts of EHA Education Sessions are well worth watching
June 14, 2011, Biotech Strategy Blog
.
Webcasts of EHA Education Sessions are well worth watching
June 14, 2011, Biotech Strategy Blog
.
